JAK1
JAK1 (Janus kinase 1, also known as JAK1A, JTK3 and JAK1B) is a non-membrane spanning protein tyrosine kinase that transmits cytokine signals from receptor complexes to STAT proteins. It has a central role in interferon and interleukin-6 family signalling. Browse Assay Genie's current range of JAK1 research reagents below, or read on for the biology behind the target.
JAK1 is a non-membrane spanning protein tyrosine kinase that phosphorylates the signal-transducing subunits of cytokine receptor complexes, including IL2RB, IL10RA, IFNAR2, IL6ST, LIFR, OSMR and IL31RA. It is involved in the IFN-alpha/beta/gamma signalling pathway. When interferon binds the IFNAR1-IFNAR2 heterodimer, JAK1 phosphorylates and activates its binding partner IFNAR2, which creates docking sites for STAT proteins. JAK1 phosphorylates STAT proteins directly. It also activates STAT signalling by transactivating other JAK kinases associated with signalling receptors.
The same mechanism operates in several other pathways. Binding of CNTF, or of the CLCF1/CLF heterodimer, to CNTFR leads to IL6ST/gp130-LIFR dimerisation and activation of JAK1 and JAK2. These kinases then phosphorylate IL6ST/gp130 and LIFR, and the phosphorylated receptors act as docking proteins for STAT3. JAK1 also acts in oncostatin-M signalling through both the type I (LIFR and IL6ST) and type II (OSMR and IL6ST) receptor complexes. It is involved in interleukin-31 signalling through the OSMR and IL31RA complex, and in the MT-RNR2/humanin pathway that leads to STAT3 phosphorylation.
The JAK1 gene encodes a member of the Tyr protein kinase family, JAK subfamily, in the protein kinase superfamily. These kinases have a second phosphotransferase-related domain immediately N-terminal to the kinase domain. HGNC places it in the FERM domain containing and Jak family tyrosine kinase groups. NCBI describes JAK1 as a key component of the IL-6/JAK1/STAT3 immune and inflammation response and as a therapeutic target for alleviating cytokine storms. It affects the expression of genes that mediate inflammation, epithelial remodelling and metastatic cancer progression. SOCS1 directly inhibits its kinase activity, and alternative splicing produces multiple transcript variants.
JAK1 phosphorylates and activates IFNAR2 after interferon binding, creating the STAT docking sites needed for IFN-alpha/beta/gamma responses.
JAK1 is a key component of the IL-6/JAK1/STAT3 axis and acts downstream of IL6ST/gp130, LIFR, OSMR and CNTFR complexes.
The IL-6/JAK1/STAT3 response is central to inflammation, and JAK1 is a therapeutic target for alleviating cytokine storms.
JAK1 influences expression of genes that mediate epithelial remodelling and metastatic cancer progression, making it relevant to tumour signalling studies.
JAK1 is a tyrosine kinase that phosphorylates cytokine receptor subunits such as IFNAR2, IL6ST and LIFR. This creates docking sites for STAT proteins, which JAK1 also phosphorylates directly. It therefore links interferon and interleukin-6 family cytokine binding to STAT-driven gene expression.
The HGNC name is Janus kinase 1, and UniProt calls the protein tyrosine-protein kinase JAK1. Aliases include JAK1A, JTK3 and JAK1B. NCBI notes that alternative splicing gives multiple transcript variants, so researchers searching for a JAK1 antibody or JAK1 ELISA kit may see several names.
A mouse ortholog, Jak1, exists. JAK1 belongs to the JAK subfamily, alongside JAK2 and JAK3. Its kinase activity is directly inhibited by suppressor of cytokine signalling 1 (SOCS1). Check the datasheet of any product for its validated reactivity.
Other Janus kinase family members with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P23458; product specifications from Assay Genie datasheets.